Head-to-Head Comparison of [18F]F-choline and Imaging of Prostate-Specific Membrane Antigen, Using [18F]DCFPyL PET/CT, in Patients with Biochemical Recurrence of Prostate Cancer

Purpose: To analyse diagnostic and therapeutic impact of molecular imaging TNM (miTNM) stage obtained with [18F]DCFPyL versus [18F]F-choline in head-to-head comparison biochemical recurrence (BCR) prostate cancer (PCa). Material methods: Patients BCR PCa after radical treatment previous [18F]F-choline-PET/CT (negative or oligometastatic disease) were recruited to [18F]DCFPyL-PET/CT. classified according to: grade group, European Association Urology classification, PSA, PSA doubling time (PSAdt) velocity (PSAvel). The overall detection rate (DR) miTNM PROMISE criteria assessed for both radiotracers also correlated (Kappa). influence kinetics on PET/CT (DR miTNM) predictive value unfavourable determined. Cut-off PSAdt PSAvel values able predict results Change derived from information compared evaluated. Results: We studied 138 patients. showed a higher DR than (64.5% 33.3%) fair agreement. detected T 33.3% 19.6%, N 27.5% 13.8%, M 30.4% 8.7%. Both tracers’ significant associations PSAvel. Significant association was only found between (p = 0.033). For [18F]DCFPyL-PET/CT, cut-off 4.09 5.59 months, respectively, stage. changed management 40/138 Conclusions: provides superior staging restaging BCR, especially high kinetics, showing agreement [18F]F-choline.